

Norimitsu Inoue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2982304/publications.pdf>

Version: 2024-02-01

48
papers

1,930
citations

279798

23
h-index

276875

41
g-index

54
all docs

54
docs citations

54
times ranked

3282
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway. <i>Journal of Immunology</i> , 2008, 180, 7175-7183.	0.8	228
2	Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2066-2071.	7.1	195
3	Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 252-257.	7.1	177
4	Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). <i>Blood</i> , 2006, 108, 4232-4236.	1.4	147
5	Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. <i>International Journal of Cancer</i> , 2013, 133, 1107-1118.	5.1	122
6	M2-like macrophage polarization in high lactic acid-producing head and neck cancer. <i>Cancer Science</i> , 2017, 108, 1128-1134.	3.9	104
7	Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in <i>PIGW1</i> is associated with West syndrome and hyperphosphatasia with mental retardation syndrome. <i>Journal of Medical Genetics</i> , 2014, 51, 203-207.	3.2	93
8	IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. <i>International Immunology</i> , 2011, 23, 29-41.	4.0	82
9	Vitamin B ₆ -responsive epilepsy due to inherited GPI deficiency. <i>Neurology</i> , 2013, 81, 1467-1469.	1.1	77
10	Dynamic Regulation of p53 Subnuclear Localization and Senescence by MORC3. <i>Molecular Biology of the Cell</i> , 2007, 18, 1701-1709.	2.1	75
11	Two-step colocalization of MORC3 with PML nuclear bodies. <i>Journal of Cell Science</i> , 2010, 123, 2014-2024.	2.0	57
12	Critical Roles of the p110 ^δ Subtype of Phosphoinositide 3-Kinase in Lipopolysaccharide-Induced Akt Activation and Negative Regulation of Nitrite Production in RAW 264.7 Cells. <i>Journal of Immunology</i> , 2008, 180, 2054-2061.	0.8	52
13	MIWI2 as an Effector of DNA Methylation and Gene Silencing in Embryonic Male Germ Cells. <i>Cell Reports</i> , 2016, 16, 2819-2828.	6.4	46
14	Protein kinase C δ binds TIRAP/Mal to participate in TLR signaling. <i>Molecular Immunology</i> , 2007, 44, 2257-2264.	2.2	45
15	Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. <i>Journal of Clinical Investigation</i> , 2019, 129, 5123-5136.	8.2	36
16	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 112-121.	1.6	31
17	IFN γ Markedly Cooperates with Intratumoral Dendritic Cell Vaccine in Dog Tumor Models. <i>Cancer Research</i> , 2010, 70, 7093-7101.	0.9	30
18	Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. <i>FEBS Letters</i> , 2007, 581, 3334-3340.	2.8	29

#	ARTICLE	IF	CITATIONS
19	Effects of laughter therapy on quality of life in patients with cancer: An open-label, randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0219065.	2.5	29
20	IRAK-4-dependent Degradation of IRAK-1 is a Negative Feedback Signal for TLR-mediated NF- κ B Activation. <i>Journal of Biochemistry</i> , 2007, 143, 295-302.	1.7	28
21	Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research - Secondary Publication. <i>Allergology International</i> , 2012, 61, 559-562.	3.3	28
22	Deregulated expression of <i>HMGA2</i> is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2012, 156, 383-387.	2.5	28
23	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. <i>Microbes and Infection</i> , 2011, 13, 350-358.	1.9	25
24	Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion. <i>Cancer Science</i> , 2010, 101, 1596-1603.	3.9	19
25	Three pentraxins C-reactive protein, serum amyloid p component and pentraxin 3 mediate complement activation using Collectin CL-P1. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1-14.	2.4	19
26	Characterization of the T α cell receptor beta chain repertoire in tumor-infiltrating lymphocytes. <i>Cancer Medicine</i> , 2016, 5, 2513-2521.	2.8	17
27	Collectin CL-P1 utilizes C-reactive protein for complement activation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 1118-1128.	2.4	17
28	An Immune-Stimulatory Helix-Loop-Helix Peptide: Selective Inhibition of CTLA-4-B7 Interaction. <i>ACS Chemical Biology</i> , 2020, 15, 360-368.	3.4	16
29	Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation. <i>International Journal of Cancer</i> , 2014, 135, 2847-2856.	5.1	15
30	Effect of IL-12 on canine dendritic cell maturation following differentiation induced by granulocyte-macrophage CSF and IL-4. <i>Veterinary Immunology and Immunopathology</i> , 2010, 137, 322-326.	1.2	10
31	A possible abscopal effect of post-irradiation immunotherapy in two patients with metastatic lung tumors. <i>International Cancer Conference Journal</i> , 2014, 3, 122-127.	0.5	8
32	Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands. <i>Cancer Science</i> , 2018, 109, 1319-1329.	3.9	8
33	The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC. <i>Auris Nasus Larynx</i> , 2020, 47, 658-667.	1.2	8
34	Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand. <i>PLoS ONE</i> , 2017, 12, e0188738.	2.5	8
35	Construction of an expression vector for improved secretion of canine IL-18. <i>Veterinary Immunology and Immunopathology</i> , 2008, 126, 388-391.	1.2	5
36	Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding. <i>Internal Medicine</i> , 2020, 59, 93-99.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Production of canine soluble CD40 ligand to induce maturation of monocyte derived dendritic cells for cancer immunotherapy. <i>Veterinary Immunology and Immunopathology</i> , 2013, 156, 121-127.	1.2	3
38	Paroxysmal Nocturnal Hemoglobinuria Caused By Pigt Mutations; Atypical PNH. <i>Blood</i> , 2016, 128, 2450-2450.	1.4	3
39	Disseminated gonococcal infection in a Japanese man with complement 7 deficiency with compound heterozygous variants. <i>Medicine (United States)</i> , 2021, 100, e25265.	1.0	2
40	Granular C3 dermatosis-like immunological manifestation found in a case of acute generalized exanthematous pustulosis: Implication for the mechanism in C3 deposition to the epidermal basement membrane zone. <i>Journal of Dermatology</i> , 2021, 48, e238-e239.	1.2	1
41	Effect of regulation of glycolysis on tumor inflammation and immune status. <i>Immunobiology</i> , 2012, 217, 1165.	1.9	0
42	Application of CR4-targeting antitumor immunoadjuvant for an advanced dendritic cell therapy. <i>Immunobiology</i> , 2016, 221, 1206-1207.	1.9	0
43	Collectin CL-P1 is involved in C-reactive protein-mediated complement activation. <i>Immunobiology</i> , 2016, 221, 1215.	1.9	0
44	Paroxysmal nocturnal hemoglobinuria caused by PIGT mutations: Atypical PNH. <i>Immunobiology</i> , 2016, 221, 1159.	1.9	0
45	Anti-complement factor H (CFH) antibodies and a novel <i>CFH</i> gene mutation in an atypical hemolytic uremic syndrome patient with complement activation of the classical pathway. <i>Immunological Medicine</i> , 2021, 44, 274-277.	2.6	0
46	GPI Mannose Extension (PIGM, PIGV, PIGB, PIGZ). , 2014, , 1209-1220.		0
47	Map 5: Biosynthetic Pathways of GPI-Anchor. , 2014, , 1687-1691.		0
48	Pathogenesis of Clonal Dominance in PNH: Growth Advantage in PNH. , 2017, , 229-251.		0